JHL Biotech Shareholders Vote to Voluntarily Delist from China's Taiwan, China Region Exchange

JHL Biotech (TPEx: 6540) announced that its shareholders voted to voluntarily delist the company's ordinary shares from the Emerging Stock Market of the Taipei Exchange (TPEx).  JHL's Board of Directors convened an Extraordinary General Meeting today for shareholders to vote on the proposal and related matters.

JHL's Board of Directors believes the voluntary delisting is in the best interests of the company and its shareholders. With the voluntary delisting, JHL will be better able to pursue its planned expansion activities and to explore various fundraising strategies (including potentially listing on an overseas exchange).

JHL has several biosimilars that are either currently in or expected to be in clinical trial in 2018, including:

Rituximab biosimilar, JHL1101, to treat rheumatoid arthritis. Currently in Phase I trial in Europe. Expected Phase III in Europe and Phase I and III in China in 2018.

Dornase alfa biosimilar, JHL1922, to manage symptoms of cystic fibrosis. Expected Phase I and Phase III trials in Europe in 2018.

Bevacizumab biosimilar, JHL1149, to treat colon and other cancers. Expected Phase I trial in Europe in 2018

Trastuzumab biosimilar, JHL1188, to treat breast cancer. Expected Phase I in Europe in 2018

JHL has submitted the relevant applications to regulators to voluntarily terminate trading of JHL shares on the Emerging Stock Market of Taipei Exchange (TPEx) and to withdraw public issuance of the shares.  The company will purchase the shares of the company as mandated by the TPEx. The purchase period will be 50 days from the termination of trading, and the exact date will be announced after obtaining the approval from TPEx. The purchase price will be determined in accordance with relevant laws. 

Register to Attend CPhI China 2018!